One brain receptor, two opposite paths to weight loss

Mounjaro and Zepbound turn a brain receptor on. MariTide turns the same one off. Both kinds of drug produce weight loss, and until now no one could cleanly explain why opposite moves at the same target both work.

A Nature Metabolism paper from the University of Cambridge's Institute of Metabolic Science gives the answer: the receptor, GIPR, controls body weight through two anatomically distinct circuits, and the new obesity drugs each talk to a different one. The team reached that conclusion with knock-in mice in which they could disable GIPR in either the area postrema (a brainstem structure) or the hypothalamus, then watch which drug still worked.

The receptor in question is GIPR, short for glucose-dependent insulinotropic polypeptide receptor. It sits next to the better-known GLP-1R that Wegovy and Ozempic target. Both receptors respond to gut-derived hormones released after a meal. GIPR has been the harder one to reason about, because clinical results pointed in two directions at once.

In one direction, Mounjaro and Zepbound activate GIPR. They are dual GIPR/GLP-1R agonists, and the GIPR arm contributes to appetite suppression and additional weight loss beyond what a GLP-1R agonist alone delivers. In the other direction, MariTide blocks GIPR. It is a GIPR antagonist combined with a GLP-1R agonist, and it also produces meaningful weight loss in trials. The two drug classes should not, on paper, both work.

The Cambridge group, based at the Institute of Metabolic Science, used two mouse lines to separate the receptor's jobs. In one line, GIPR was knocked out specifically in the area postrema, the brainstem region that senses circulating hormones. In the other, GIPR was knocked out in hypothalamic neurons. Each line removed the receptor from one site while leaving the other intact.

When the team gave acyl-GIP, a GIPR activator, to the brainstem-knockout mice, the drug no longer suppressed appetite. The hypothalamic-knockout mice still responded. That placed the appetite-suppressing effect of GIPR activation in the area postrema, consistent with the brainstem's role as a chokepoint for blood-borne signals.

The opposite pattern showed up for GIPR antagonism. Blocking the receptor in the hypothalamus, not the brainstem, was what unlocked weight loss. The team's reading, laid out in the Cambridge newsroom release, is that hypothalamic GIPR normally acts as a brake on fullness signals from elsewhere in the brain. Removing the brake, by blocking the receptor, lets those signals land. Turning the receptor on, in the brainstem, suppresses appetite through a different route.

The two effects converge on the same outcome, weight loss, but through different regional logic. That is the headline mechanism. It is also the part that lets drug designers reason about combination therapy.

Both GIPR activators and GIPR antagonists add weight loss on top of GLP-1R agonism in preclinical models, the paper reports. The clinical implication is direct: pairing a GIPR modulator with the Wegovy or Ozempic family, in either direction, is a viable next move, and the choice of direction can be tuned to which side-effect profile a developer wants to manage. ScienceDaily's writeup and SciTechDaily's coverage both highlight the same combination angle, framing the regional map as a design tool for the next wave of obesity drugs.

The Cambridge statement frames the practical prize as designing drugs that produce more weight loss with fewer side effects, by sending each molecule to the brain region where it does useful work and away from the region where it causes problems.

The regional split is demonstrated in mice, not in human imaging, and the Nature Metabolism full text is paywalled and partially truncated in the version this piece drew from, so quantitative effect sizes and dose-response curves are not yet verifiable from the excerpts. The combination-therapy implication is preclinical. GLP-1-class drugs have known gastrointestinal side effects, supply constraints, and access issues that no brain-map fix will resolve on its own. More than a billion people worldwide live with obesity, and the public-health case for better drugs is large, but the next step is human trials that test whether the brainstem-versus-hypothalamus split holds.

Genetic Engineering and Biotechnology News treats the result as the field's first clean explanation for a paradox that has been visible in clinical data for years. The Nature Metabolism paper is the durable artifact; the watch item is whether GIPR-agonist-plus-GLP-1 and GIPR-antagonist-plus-GLP-1 combination trials report the same regional split in humans. The first readouts from those programs will tell readers whether the mouse map is also the human map.